Navigation Links
Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
Date:1/6/2012

REDWOOD CITY, Calif., Jan. 6, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD. The first of these two trials (NCT01349803) was a 237-subject cardiovascular safety study designed to measure the change in mean heart rate following twice-daily (BID) chronic administration of the combination PT003, and its components PT001 and PT005. The second (NCT01349816) was a 185-patient, randomized, double-blind dose-confirmation study of different doses of PT003 compared with its components. PT003, PT001 and PT005 were shown to be safe, effective and well tolerated, with no meaningful changes in heart rate or other cardiovascular safety parameters relative to baseline as measured by Holter monitor over two weeks. Pearl plans to present results of these trials at appropriate medical meetings in 2012.

"We were able to conduct these two studies, as well as the previously announced Phase 2b dose-ranging studies of PT001 and PT005 in approximately six months, which is a testament to both the skill and commitment of our clinical team, and the efficacy and safety profiles of our combination bronchodilator observed to date," said Chuck Bramlage, chief executive officer for Pearl Therapeutics. "With this operational excellence, along with the continued safety and efficacy of our bronchodilator combination, we are confident in our plan to advance PT003, PT001 and PT005 into the rigor of late-stage clinical scrutiny."

These two clinical trials are part of the Company's five-study Phase 2b program that included three previously completed, randomized, double-blind trials: one dose-ranging trial each of PT005 and PT001, plus a placebo- and active-controlled
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
3. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
6. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
7. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
8. Pearl Therapeutics Bronchodilator Combination PT003 Provides Superior Inspiratory Capacity Compared to Spiriva®
9. Anthera Announces Last Patient Enrolled in PEARL-SC Study
10. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
11. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 In response to urgent requests ... Sierra Leone , Direct Relief delivered two ... for the treatment of local health workers who contract Ebola ... dedicated Ebola care center was constructed for foreign health care ... not available for local Sierra Leonean health workers. ...
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2
... , SALT LAKE CITY , March 15 Otix Global, Inc. (Nasdaq: OTIX ), announced today that it ... to April 11, 2011 , modifies covenants, and revises the borrowing base formula which allows the Company to obtain additional funds ... ... , ...
... March 14 Siemens Healthcare addresses the ... 59th Annual Scientific Session of the American College of Cardiology ... booth #1018. With a commitment to excellence, Siemens empowers its ... world of cardiology, and help them meet their strategic and ...
Cached Medicine Technology:Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 2Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 2Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 3Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 4Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 5Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 6Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 7Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 8Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 9Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 10Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 11Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 12Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 13Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010 14
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... Dr. Robert S. Bray, Jr. of ... D.I.S.C. Spine and Sports Center, ... dream after successfully qualifying for the 2008 Olympics Saturday in,Atlanta ... country,s preeminent,neurological spinal surgeons specializing in micro procedures. Bray,performed a ...
... Appears Superior to Standard Therapy for Eradicating H. ... trials comparing sequential and standard triple therapies in ... infection found that sequential therapy appears superior to ... infection. , Authors say if further trials ...
... The St. Jude Dream Home(R) in,Hurricane, W. Va., is ... CertainTeed Gypsum Plant in nearby Moundsville, W. Va. To ... CertainTeed is,donating gypsum wallboard and roofing shingles that will ... ), The 3,100 square foot St. Jude Dream ...
... FLARE Santa,Clara HIV County Collaborative: PACE Clinic, Asian ... Lesbian and Gay Community,Center, Song That Radio, Santa ... Wellness Center present a performance art contest at,DeAnza ... 11 to 2 PM., The midday celebration ...
... SANTA PAULA, Calif., May 19 Today, the ... provides the,most highly trained canine-firefighter disaster search teams ... $4.1 million 122-acre ranch site in Santa,Paula, California, ... its kind.,The National Training Center (NTC) will allow ...
... skin open to infection, study says , , MONDAY, ... polyalkylimide implant injections may cause infrequent, but sometimes severe, ... , These implants, which consist of gel and ... such as the lips, cheeks, forehead and lines that ...
Cached Medicine News:Health News:Successful Back Surgery Propels Olympic Weightlifting Hopeful Melanie Roach to Realize Her Dreams Of Participating in the 2008 Beijing Olympics 2Health News:Gypsum Wallboard from CertainTeed's Moundsville, W. Va., Plant and Roofing Shingles among Building Materials Donated to St. Jude Dream Home(R) 2Health News:National Disaster Search Dog Foundation Plans New Training Facility in Santa Paula, California 2Health News:Cosmetic Skin Fillers May Cause Delayed Side Effects 2
Cushing forceps. Insulated....
Scleral knives designed for trabeculectomy and groove type incisions, scleral standard USA size....
Angled 60 degree blades 5.5 mm....
Fechtner Trabeculectomy Marker...
Medicine Products: